CD274 and cancer: Strategies such as use of checkpoint inhibitors (e.g. anti-PD-1 or anti-PD-L1) to block PD-1 and PD-L1 interaction between CAR-T cells and cancer cells are being used in clinical trials to restore CAR-T cell function (15, 16).